Company Overview and News
A1 Consolidated Gold Ltd (ASX:AYC) is an emerging junior Victorian gold producer that is developing the A1 Gold Mine. The company’s has a fully permitted 150,000tpa gold processing facility. A1 Consolidated has today been granted a trading halt by the ASX, pending details of a capital raising. The halt will remain in place until the opening of trade on Wednesday 27th July 2016, or earlier if an announcement is made to the market.
A1 Consolidated Gold Ltd (ASX:AYC) has milled 1,558 tonnes at 24.9 g/t gold mined from the A1 Gold Mine near Woods Point, Victoria during June. The milling was done at the Porcupine Flat processing Plant near Maldon and achieved 97.8% recovery. A1’s gold sales in June were in excess of $1.4 million. The mined ore was obtained from drilling at the A1 Gold Mine as part of a resource upgrade for the Phase 1 Drill Target area.
A1 Consolidated Gold Ltd (ASX:AYC) has reported a 200% higher grade resource of 9,600 ounces gold at 10.50 g/t from Phase 1 Target Area of the A1 Gold Mine near Woods Point, Victoria. The total resource at the project is 281,200 ounces. This includes the first ever measured resource of 5,000 tonnes for 2500 ounces of gold at a high grade of 15.53 g/t. A1’s drilling, assaying and modelling over the last 8 weeks is valued at over $17 million at today’s prices.
Mantle Mining Corporation Ltd (ASX:MNM) is edging closer to a re-start of mining at its newly acquired Morning Star gold mine in the gold fields of Victoria. With a scond payment of $1 million to the vendor of Morning Star gold mine, it has two more payments to complete the acquisition price for the mine in eastern Victoria. In the late 1950’s Morning Star was one of Australia’s largest gold mines having reportedly produced in excess of 800,000 ounces of gold at an average grade of 26.
2018-04-25 - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
2018-04-25 - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...